{"schema_version":"1","generated_at":"2026-11-08T11:02:58.288Z","data_as_of":null,"url":"https://www.findmykol.com/kol/lindsey-beffa","json_url":"https://www.findmykol.com/kol/lindsey-beffa/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"lindsey-beffa","name":"Lindsey Beffa","credential":"MD","specialty":"Gynecologic Oncology","specialty_raw":"Gynecologic Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Cleveland Clinic","institution_url":"https://www.findmykol.com/institution/cleveland-clinic","city":"Cleveland","state":"OH","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1134415029","orcid":"0000-0003-0410-8169","openalex":"A5048917713"},"summary":"Lindsey Beffa is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 49 publications with 1,028 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":49,"cited_by_count":1028,"h_index":8,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":2,"shown":2,"withheld":0,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":43.25,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1134415029"},{"payer":"ABBVIE INC.","program_year":2024,"amount_usd":98.17,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1134415029"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1134415029","source":"payments"},"prescribing":{"data_year":2023,"areas_total":3,"areas_shown":3,"areas":[{"area":"Nervous system","share_pct":63.9,"classes_total":3,"classes":[{"class":"Opioid Agonist","setting":"prescribed","share_pct":29.2,"drugs":[{"name":"Oxycodone Hcl","share_pct":100}],"max_beneficiaries":20},{"class":"Nonsteroidal Anti-inflammatory Drug","setting":"prescribed","share_pct":19.4,"drugs":[{"name":"Ibuprofen","share_pct":100}],"max_beneficiaries":13}]},{"area":"Cancer & immunology","share_pct":18.1,"classes_total":1,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":18.1,"drugs":[{"name":"Lenvima","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":18.1,"classes_total":1,"classes":[{"class":"Polyene Antifungal","setting":"prescribed","share_pct":18.1,"drugs":[{"name":"Nystatin","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":49,"shown":5,"withheld":44,"matched_by":"OpenAlex author record","recent":[{"title":"Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.5502","status":"verified"},{"title":"Acute Encephalopathy during First Pembrolizumab Infusion Followed by Delayed Multisystem Immune Toxicity in Recurrent Vaginal Cancer: A Case Report","year":2026,"journal":"Case Reports in Oncology","source_url":"https://doi.org/10.1159/cro/abzag026","status":"verified"},{"title":"Molecular sub group and post immunotherapy analysis: Results from NRG GY012","year":2026,"journal":"Gynecologic Oncology","source_url":"https://doi.org/10.1016/j.ygyno.2026.01.780","status":"verified"},{"title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","year":2025,"journal":"Nature Medicine","source_url":"https://doi.org/10.1038/s41591-025-03566-1","status":"verified"},{"title":"Patient-reported outcomes of phase III randomized, placebo-controlled study of pembrolizumab plus chemotherapy for advanced endometrial cancer (NRG GY018)","year":2025,"journal":"Gynecologic Oncology","source_url":"https://doi.org/10.1016/j.ygyno.2025.04.511","status":"verified"}],"source":"works"},"similar":[{"name":"Steven Nissen","slug":"steven-nissen","institution":"Cleveland Clinic","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/steven-nissen","json_url":"https://www.findmykol.com/kol/steven-nissen/profile.json"},{"name":"Samir Kapadia","slug":"samir-kapadia","institution":"Cleveland Clinic","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/samir-kapadia","json_url":"https://www.findmykol.com/kol/samir-kapadia/profile.json"},{"name":"Mina Chung","slug":"mina-chung","institution":"Cleveland Clinic","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/mina-chung","json_url":"https://www.findmykol.com/kol/mina-chung/profile.json"},{"name":"Serpil Erzurum","slug":"serpil-erzurum","institution":"Cleveland Clinic","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/serpil-erzurum","json_url":"https://www.findmykol.com/kol/serpil-erzurum/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":44}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}